Annual CFO
-$127.49 M
-$34.76 M-37.49%
December 31, 2024
Summary
- As of February 23, 2025, KPTI annual cash flow from operations is -$127.49 million, with the most recent change of -$34.76 million (-37.49%) on December 31, 2024.
- During the last 3 years, KPTI annual CFO has fallen by -$20.37 million (-19.02%).
- KPTI annual CFO is now -1391.24% below its all-time high of -$8.55 million, reached on December 31, 2011.
Performance
KPTI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
December 31, 2024
Summary
- KPTI quarterly cash flow from operations is not available.
Performance
KPTI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
December 31, 2024
Summary
- KPTI TTM cash flow from operations is not available.
Performance
KPTI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
KPTI Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -37.5% | - | - |
| 3 y3 years | -19.0% | - | - |
| 5 y5 years | +33.2% | - | - |
KPTI Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -37.5% | +14.8% | ||||
| 5 y | 5-year | -37.5% | +33.2% | ||||
| alltime | all time | -1391.2% | +33.2% |
Karyopharm Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$127.49 M(+37.5%) | - | - |
| Sep 2024 | - | -$19.45 M(-49.5%) | -$120.26 M(-7.7%) |
| Jun 2024 | - | -$38.50 M(-12.0%) | -$130.34 M(+10.9%) |
| Mar 2024 | - | -$43.73 M(+135.3%) | -$117.54 M(+26.8%) |
| Dec 2023 | -$92.72 M(-38.0%) | -$18.59 M(-37.1%) | -$92.72 M(-8.2%) |
| Sep 2023 | - | -$29.53 M(+14.9%) | -$100.98 M(+1.2%) |
| Jun 2023 | - | -$25.70 M(+35.9%) | -$99.82 M(-8.6%) |
| Mar 2023 | - | -$18.91 M(-29.6%) | -$109.27 M(-26.9%) |
| Dec 2022 | -$149.55 M(+39.6%) | -$26.84 M(-5.4%) | -$149.55 M(+53.8%) |
| Sep 2022 | - | -$28.37 M(-19.3%) | -$97.24 M(+4.8%) |
| Jun 2022 | - | -$35.14 M(-40.6%) | -$92.82 M(-18.2%) |
| Mar 2022 | - | -$59.20 M(-332.4%) | -$113.42 M(+5.9%) |
| Dec 2021 | -$107.12 M(-33.2%) | $25.48 M(-206.3%) | -$107.12 M(-34.4%) |
| Sep 2021 | - | -$23.95 M(-57.0%) | -$163.22 M(-11.1%) |
| Jun 2021 | - | -$55.75 M(+5.4%) | -$183.58 M(+9.2%) |
| Mar 2021 | - | -$52.89 M(+72.6%) | -$168.11 M(+4.9%) |
| Dec 2020 | -$160.23 M(-16.0%) | -$30.63 M(-30.9%) | -$160.23 M(-5.2%) |
| Sep 2020 | - | -$44.31 M(+10.0%) | -$169.09 M(+4.8%) |
| Jun 2020 | - | -$40.28 M(-10.5%) | -$161.28 M(-4.7%) |
| Mar 2020 | - | -$45.01 M(+14.0%) | -$169.21 M(-11.3%) |
| Dec 2019 | -$190.82 M(+19.9%) | -$39.49 M(+8.2%) | -$190.82 M(-4.4%) |
| Sep 2019 | - | -$36.51 M(-24.3%) | -$199.50 M(-1.1%) |
| Jun 2019 | - | -$48.20 M(-27.6%) | -$201.66 M(+5.5%) |
| Mar 2019 | - | -$66.62 M(+38.3%) | -$191.09 M(+20.1%) |
| Dec 2018 | -$159.12 M | -$48.17 M(+24.6%) | -$159.12 M(+36.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$38.66 M(+2.8%) | -$116.48 M(+17.0%) |
| Jun 2018 | - | -$37.63 M(+8.6%) | -$99.57 M(+19.0%) |
| Mar 2018 | - | -$34.65 M(+525.7%) | -$83.66 M(+13.5%) |
| Dec 2017 | -$73.72 M(-12.6%) | -$5.54 M(-74.5%) | -$73.72 M(-16.4%) |
| Sep 2017 | - | -$21.75 M(+0.1%) | -$88.18 M(+1.6%) |
| Jun 2017 | - | -$21.72 M(-12.1%) | -$86.76 M(+1.0%) |
| Mar 2017 | - | -$24.71 M(+23.6%) | -$85.93 M(+1.8%) |
| Dec 2016 | -$84.39 M(-10.3%) | -$20.00 M(-1.7%) | -$84.39 M(-0.4%) |
| Sep 2016 | - | -$20.33 M(-2.7%) | -$84.77 M(-5.6%) |
| Jun 2016 | - | -$20.89 M(-9.8%) | -$89.76 M(-7.4%) |
| Mar 2016 | - | -$23.16 M(+13.7%) | -$96.97 M(+3.1%) |
| Dec 2015 | -$94.03 M(+82.8%) | -$20.38 M(-19.6%) | -$94.03 M(+8.8%) |
| Sep 2015 | - | -$25.33 M(-9.9%) | -$86.42 M(+11.8%) |
| Jun 2015 | - | -$28.10 M(+38.9%) | -$77.32 M(+26.5%) |
| Mar 2015 | - | -$20.23 M(+58.4%) | -$61.10 M(+18.8%) |
| Dec 2014 | -$51.45 M(+69.8%) | -$12.77 M(-21.3%) | -$51.45 M(+5.5%) |
| Sep 2014 | - | -$16.23 M(+36.6%) | -$48.76 M(+17.7%) |
| Jun 2014 | - | -$11.88 M(+12.4%) | -$41.43 M(+16.0%) |
| Mar 2014 | - | -$10.57 M(+4.9%) | -$35.70 M(+17.9%) |
| Dec 2013 | -$30.29 M(+95.3%) | -$10.08 M(+13.2%) | -$30.29 M(+49.9%) |
| Sep 2013 | - | -$8.90 M(+44.6%) | -$20.21 M(+78.7%) |
| Jun 2013 | - | -$6.16 M(+19.4%) | -$11.31 M(+119.4%) |
| Mar 2013 | - | -$5.16 M | -$5.16 M |
| Dec 2012 | -$15.51 M(+81.4%) | - | - |
| Dec 2011 | -$8.55 M | - | - |
FAQ
- What is Karyopharm Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual CFO year-on-year change?
- What is the all time high quarterly CFO for Karyopharm Therapeutics?
- What is the all time high TTM CFO for Karyopharm Therapeutics?
What is Karyopharm Therapeutics annual cash flow from operations?
The current annual CFO of KPTI is -$127.49 M
What is the all time high annual CFO for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual cash flow from operations is -$8.55 M
What is Karyopharm Therapeutics annual CFO year-on-year change?
Over the past year, KPTI annual cash flow from operations has changed by -$34.76 M (-37.49%)
What is the all time high quarterly CFO for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly cash flow from operations is $25.48 M
What is the all time high TTM CFO for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM cash flow from operations is -$5.16 M